Scarica l'app Stockscreener
0.3873
1.39%
0.0053
Dopo l'orario di chiusura:
.39
0.0027
+0.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.382
Aprire:
$0.3902
Volume 24 ore:
3.36M
Relative Volume:
1.20
Capitalizzazione di mercato:
$73.31M
Reddito:
$150.71M
Utile/perdita netta:
$-30.94M
Rapporto P/E:
-2.1919
EPS:
-0.1767
Flusso di cassa netto:
$-20.86M
1 W Prestazione:
-5.17%
1M Prestazione:
-54.44%
6M Prestazione:
-69.50%
1 anno Prestazione:
-80.14%
Intervallo 1D:
$0.3851
$0.405
Intervallo di 1 settimana:
$0.382
$0.4211
Portata 52W:
$0.382
$2.30
Heron Therapeutics Inc Stock (HRTX) Company Profile
Nome
Heron Therapeutics Inc
Settore
Industria
Telefono
(858) 251-4400
Indirizzo
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Compare HRTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HRTX
Heron Therapeutics Inc
|
0.3873 | 76.49M | 150.71M | -30.94M | -20.86M | -0.1767 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-06-03 | Downgrade | Needham | Buy → Hold |
| 2025-06-09 | Iniziato | H.C. Wainwright | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2024-04-23 | Iniziato | CapitalOne | Overweight |
| 2024-03-13 | Reiterato | Needham | Buy |
| 2020-05-27 | Iniziato | Guggenheim | Buy |
| 2020-02-20 | Reiterato | Needham | Buy |
| 2019-01-16 | Reiterato | Needham | Buy |
| 2018-04-05 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Reiterato | Mizuho | Buy |
| 2018-03-01 | Reiterato | Needham | Buy |
| 2018-01-03 | Iniziato | Leerink Partners | Outperform |
| 2017-09-27 | Iniziato | Northland Capital | Outperform |
| 2017-02-27 | Iniziato | Needham | Buy |
| 2016-10-26 | Iniziato | Aegis Capital | Buy |
| 2016-09-06 | Ripresa | Lake Street | Buy |
| 2016-05-03 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-10 | Iniziato | Lake Street | Buy |
| 2015-09-23 | Reiterato | Leerink Partners | Outperform |
| 2015-09-02 | Iniziato | BofA/Merrill | Buy |
| 2015-08-03 | Reiterato | Brean Capital | Buy |
| 2015-06-30 | Reiterato | JMP Securities | Mkt Outperform |
| 2015-06-19 | Reiterato | Leerink Partners | Outperform |
| 2014-08-07 | Iniziato | Noble Financial | Buy |
Mostra tutto
Heron Therapeutics Inc Borsa (HRTX) Ultime notizie
HRTX: All director nominees and proposals were approved, with no questions from stockholders - TradingView
HRTX Q1 2026 Earnings: Deep EPS Miss Triggers 10.7% Stock DeclineGuidance Accuracy Score - newsline.com
Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade) - Seeking Alpha
Heron Therapeutics (HRTX) EVP converts 12,500 RSUs into common shares - Stock Titan
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $2 - Moomoo
TANG KEVIN C's Strategic Acquisition in Aurinia Pharmaceuticals Inc - GuruFocus
HRTX Maintains Buy Rating -- Price Target Lowered to $2.00 by HC Wainwright - GuruFocus
Heron Therapeutics Appeals Ruling Invalidating CINVANTI Patents - The Globe and Mail
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $2 - Moomoo
HRTX Downgraded by Needham -- Outlook Adjusted to Hold - GuruFocus
Heron Therapeutics to Appeal Delaware Court Ruling Invalidating CINVANTI® Patents - Minichart
Why Did FULC, MVIS, HRTX Stocks Plunge To 52-Week Lows Today? - Stocktwits
CINVANTI patent claims invalidated as Heron Therapeutics (NASDAQ: HRTX) plans appeal - Stock Titan
Heron announces U.S. district court decision regarding Cinvanti patents - TipRanks
Heron Therapeutics loses patent case over Cinvanti drug - Investing.com UK
Heron Therapeutics loses patent case over Cinvanti drug By Investing.com - Investing.com India
U.S. District Court Issues Decision Regarding CINVANTI® Patents - GlobeNewswire
Court rules CINVANTI patents invalid; Heron readies appeal - Stock Titan
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA - MSN
Number of shareholders of Heron Therapeutics, Inc. – NASDAQ:HRTX - TradingView
HRTX PE Ratio & Valuation, Is HRTX Overvalued - Intellectia AI
Heron Therapeutics (HRTX) Slides to $0.86 as Selling Pressure PersistsLinear Regression - newsline.com
Acute care revenue growth helps Heron (HRTX) reaffirm 2026 guidance despite Q1 sales decline - MSN
Heron Therapeutics (HRTX) Gains 3% as Biotech Stock Tests Key Resistance at $0.91Symmetrical Triangle - newsline.com
Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright? - Insider Monkey
Heron Therapeutics (HRTX) Price Target Lowered to $4 by H.C. WainwrightStrong Earnings Momentum - newsline.com
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74 - MSN
Heron Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HRTX) 2026-05-16 - Seeking Alpha
HRTX Stock Price, Quote & Chart | HERON THERAPEUTICS INC (NASDAQ:HRTX) - ChartMill
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX) - Stock Titan
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Heron Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3 - Moomoo
H.C. Wainwright cuts Heron Therapeutics stock price target on weak Q1 results - Investing.com
TradingKey - TradingKey
Heron (HRTX) Q1 2026 Earnings Call Transcript - AOL.com
Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX - Moomoo
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus - Investing.com Canada
Heron Therapeutics Q1 earnings call highlights - MSN
Heron Therapeutics Faces Tight Covenant Constraints That Threaten Liquidity and Strategic Flexibility - TipRanks
Heron Therapeutics 1Q Loss/Shr 4c >HRTX - Moomoo
Heron Therapeutics Signals Recovery Despite Soft Q1 - TipRanks
Heron Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Heron Therapeutics, Inc. Form 10-Q: Financial Results, Forward-Looking Statements, and Key Risks for Q1 2026 - Minichart
Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Heron Therapeutics Inc Azioni (HRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Heron Therapeutics Inc Azioni (HRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Morgan Adam | Director |
Aug 08 '25 |
Buy |
1.50 |
1,766,546 |
2,649,819 |
8,753,290 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):